Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05376917
Other study ID # 2020-03-CHRMT
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 30, 2023
Est. completion date April 30, 2025

Study information

Verified date June 2023
Source Centre Hospitalier Régional Metz-Thionville
Contact Jean-Marc PERONE, MD
Phone 387557777
Email jm.perone@chr-metz-thionville.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is multicenter, prospective, comparative and randomized study focusing on the evolution of the quality of Life and Uncorrected Binocular Visual Acuity (UBVA) evaluation at 3 months after cataract surgery in patients who underwent 4 different types of intraocular lens Implant (IOL) combinations.


Description:

Cataract, linked to the loss of transparency of the lens, is the leading cause of blindness in the world. It requires exclusively surgical treatment. Cataract surgery by ultrasonic phacoemulsification is the most common surgical procedure in France (800,000/year). The lens is removed and replaced with an artificial intraocular lens. There are different types of implants that can be used. The simplest is the monofocal implant which is implanted in such a way as to correct "only far or near vision". For near vision or vice versa, it is therefore necessary to wear corrective lenses after the operation. A technique that eliminates the need for distance and near correction is based on monovision. This is a presbyopia compensation technique that aims to induce a slight myopization of one eye for near vision (usually the dominated eye) the other eye being intended for distance vision (dominant eye). There is therefore a difference in correction and perception of the images. Depending on the fixed distance, one eye will see sharp, the other less clear, even blurry. This difference can lead to a reduction in the perception of relief. Other methods of compensating for presbyopia include the use of so-called multifocal or extended depth of field implants; they are also not devoid of sometimes annoying side effects (in particular possible halos around light sources at night) which can lead in rare cases to the removal of the intraocular lens. However, patient requirements in terms of comfort of vision and independence from glasses are increasingly high and patients themselves are increasingly informed of the existence of multifocal implants. The choice of the intraocular implant to use is therefore a real challenge, especially since patients are often still active on a professional level. Moreover, there is a lack of scientific consensus related to the choice of implants, during a surgical treatment of cataract lenses by phakoexeresis, for otherwise healthy eyes and in a subject wishing to no longer wear glasses postoperatively. . Different studies have emerged comparing the bilateral implantation of different types of multifocal implants with each other, but there is little work concerning mixed batches of "mix - match" implants.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date April 30, 2025
Est. primary completion date January 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient suffering from bilateral cataract and undergoing cataract surgery - Patient with preoperative visual acuity = 8/10th Monoyer (=+ 0.1 logMar) in each eye - Patient with nuclear color (NC), cortical (C) or posterior capsule opacity (P) cataract of normal to severe density in the Lens Opacities Classification System III (LOCSIII) - Patient with cortical cataracts classified C1 to C5 - Patient with cataracts classified as nuclear opalescence (NO)1 to NO4 and nuclear color (NC)1 to NC4 - Patient with posterior capsule opacity cataracts classified as grade 5 (P1-P5) - Patient affiliated to a social security scheme - Patient having given written consent Exclusion Criteria: - Patient with biometrics = 17 Diopters (D) and = 28D - Patient with a history (ATCD) of refractive surgery - Patient with ATCD intraocular surgery - Patient with ATCD strabismus - Patient with amblyopia - Patient with monophthalmos - Patient with age-related macular degeneration (AMD) - Patient with glaucoma - Patient with diabetic retinopathy or maculopathy - Patient with progressive or old ocular inflammatory disease - Patient presenting with a very dense nuclear cataract (Stage NO5-6, NC5-6 on the LOCSIII classification), sources of preoperative complication - Patient with keratoconus - Patient with pseudoexfoliative syndrome - Patient with pigment dispersion - Patient with traumatic cataract - Patient with astigmatism conforming to the rule > 1.5 Diopters (D) or inverse to the rule > 1 Diopter (D) - Patient with abnormal ocular morphology - Patient with abnormal keratometry - Insulin-dependent diabetics and/or diabetics with retinal complications - Pregnant or breastfeeding women - Patient under legal protection (guardianship, curators, safeguard of justice) - Person deprived of liberty - Patient wishing to see near or far exclusively

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Zeiss CT Asphina / Zeiss CT Asphina
Monovision with refractive target of -1.50D on the dominated eye
Zeiss AT Lara/ Zeiss AT Lisa Tri
Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
Zeiss CT Asphina/ Zeiss AT Lara
Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
Zeiss AT Lara / Zeiss AT Lara
Micromonovision with refractive target of -0.75D on the non-dominant eye

Locations

Country Name City State
France CHR Metz-Thionville/Hopital de Mercy Metz
France CHR Metz-Thionville_Hopital Bel Air Metz

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Régional Metz-Thionville

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary National Eye Institute Visual Functioning Questionnaire - 25 (NEI VFQ-25) questionnaire score before cataract surgery Quality of life score is obtained using the National Eye Institute Visual Functioning Questionnaire - 25 (NEI VQF-25) questionnaire score and measured before intervention.
NEI VFQ-25 questionnaire measures the dimensions of self-reported vision-targeted health status that are most important for persons who have chronic eye diseases.
The Visual Function Questionnaire (VFQ-25) consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points (100 is the best score), respectively.
Few days before surgery
Primary National Eye Institute Visual Functioning Questionnaire - 25 (NEI VFQ-25) questionnaire score 3 months after surgery Quality of life score is obtained using the National Eye Institute Visual Functioning Questionnaire - 25 (NEI VQF-25) questionnaire score and measured 3 months after intervention.
NEI VFQ-25 questionnaire measures the dimensions of self-reported vision-targeted health status that are most important for persons who have chronic eye diseases.
The Visual Function Questionnaire-25 (VFQ-25) consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points (100 is the best score), respectively.
3 months after surgery
Secondary Uncorrected binocular visual acuity for far vision measured before intervention Uncorrected binocular visual acuity for distance vision is measured before intervention using Monoyer scale for far vision, scores ranging from 1 to 10, higher scores mean a better outcome; score 10 is the best. Few days before surgery
Secondary Uncorrected binocular visual acuity for intermediate vision measured before intervention Uncorrected binocular visual acuity is measured before intervention using Parinaud scale for intermediate vision.
The Parinaud scale ranges from Parinaud 14 (P 14) (lowest score) to Parinaud 1.5 (P 1.5) (best score).
Few days before surgery
Secondary Uncorrected binocular visual acuity for near vision measured before intervention Uncorrected binocular visual acuity is measured before intervention using Parinaud scale for near vision.
The Parinaud scale ranges from Parinaud 14 (P 14) (lowest score) to Parinaud 1.5 (P 1.5) (best score).
Few days before surgery
Secondary Uncorrected binocular visual acuity for far vision measured 4 days postoperatively Uncorrected binocular visual acuity for far vision is measured 4 days postoperatively using Monoyer scale for far vision, scores ranging from 1 to 10, higher scores mean a better outcome; score 10 is the best. 4 days after surgery
Secondary Uncorrected binocular visual acuity for intermediate vision measured 4 days postoperatively Uncorrected binocular visual acuity for intermediate vision is measured 4 days postoperatively using Parinaud scale.
The Parinaud scale ranges from Parinaud 14 (P 14) (lowest score) to Parinaud 1.5 (P 1.5) (best score).
4 days after surgery
Secondary Uncorrected binocular visual acuity for far vision measured 1 month postoperatively Uncorrected binocular visual acuity is measured 1 month after surgery using Monoyer scale for far vision, scores ranging from 1 to 10, higher scores mean a better outcome; score 10 is the best. 1 month after surgery
Secondary Uncorrected binocular visual acuity for intermediate vision measured 1 month postoperatively Uncorrected binocular visual acuity is measured 1 month after surgery using Parinaud scale.
The Parinaud scale ranges from Parinaud 14 (P 14) (lowest score) to Parinaud 1.5 (P 1.5) (best score).
1 month after surgery
Secondary Uncorrected binocular visual acuity for near vision measured 1 month postoperatively Uncorrected binocular visual acuity is measured 1 month after surgery using Parinaud scale.
The Parinaud scale ranges from Parinaud 14 (P 14) (lowest score) to Parinaud 1.5 (P 1.5) (best score).
1 month after surgery
Secondary Uncorrected binocular visual acuity for far vision measured 3 months postoperatively Uncorrected binocular visual acuity is measured 3 months after surgery using Monoyer scale for far vision, scores ranging from 1 to 10, higher scores mean a better outcome; score 10 is the best. 3 months after surgery
Secondary Uncorrected binocular visual acuity for intermediate vision measured 3 months postoperatively Uncorrected binocular visual acuity for intermediate vision is measured 3 months after surgery using Parinaud scale.
The Parinaud scale ranges from Parinaud 14 (P 14) (lowest score) to Parinaud 1.5 (P 1.5) (best score).
3 months after surgery
Secondary Uncorrected binocular visual acuity for near vision measured 3 months postoperatively Uncorrected binocular visual acuity for near vision is measured 3 months after surgery using Parinaud scale.
The Parinaud scale ranges from Parinaud 14 (P 14) (lowest score) to Parinaud 1.5 (P 1.5) (best score).
3 months after surgery
Secondary Sunglasses wear frequency 3 months after surgery for far and near visions Frequency of wearing sunglasses in patients undergoing IOL implant surgery : permanently (yes/no) or occasionally (yes/no) for far and near visions 3 months after surgery
Secondary Eye tonicity before surgery Eye pressure measurement millimeters of mercury (mmHg) before intervention Few days before surgery
Secondary Eye tonicity 4 days postoperatively Eye pressure measurement millimeters of mercury (mmHg) 4 days postoperatively 4 days after surgery
Secondary Eye tonicity 1 month postoperatively Eye pressure measurement millimeters of mercury (mmHg) 1 month postoperatively 1 month after surgery
Secondary Eye tonicity 3 months postoperatively Eye pressure measurement millimeters of mercury (mmHg) 3 months postoperatively 3 months after surgery
Secondary Slit lamp and Macular Optical coherence tomography (OCT) examination before surgery Presence of postoperative complications: Persistent lens mass (Yes/No); Tyndall effect (Yes/No) Hyphema (Yes/No); Irian hernia (Yes/No); Endophthalmitis (Yes/No); Implant dislocation (Yes/No) Few days before surgery
Secondary Slit lamp and Macular OCT examination 4 days postoperatively Presence of postoperative complications: Persistent lens mass (Yes/No); Tyndall effect (Yes/No) Hyphema (Yes/No); Irian hernia (Yes/No); Endophthalmitis (Yes/No); Implant dislocation (Yes/No) 4 days after surgery
Secondary Slit lamp and Macular OCT examination 1 month postoperatively Presence of postoperative complications: Persistent lens mass (Yes/No); Tyndall effect (Yes/No); Hyphema (Yes/No); Irian hernia (Yes/No); Endophthalmitis (Yes/No); Implant dislocation (Yes/No) 1 month after surgery
Secondary Slit lamp and Macular OCT examination 3 months postoperatively Presence of postoperative complications: Persistent lens mass (Yes/No); Tyndall effect (Yes/No); Hyphema (Yes/No); Irian hernia (Yes/No); Endophthalmitis (Yes/No); Implant dislocation (Yes/No) 3 months after surgery
See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A